CalciMedica (NASDAQ:CALC) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock.

CalciMedica Trading Up 2.1 %

NASDAQ:CALC opened at $1.95 on Tuesday. The stock has a 50-day moving average price of $2.34 and a 200 day moving average price of $3.11. The stock has a market capitalization of $26.29 million, a P/E ratio of -1.81 and a beta of 1.20. CalciMedica has a 12-month low of $1.81 and a 12-month high of $6.27.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.14. On average, research analysts predict that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of CalciMedica

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cetera Investment Advisers boosted its holdings in shares of CalciMedica by 37.1% during the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock valued at $60,000 after purchasing an additional 4,566 shares during the last quarter. Atria Investments Inc lifted its position in shares of CalciMedica by 28.3% in the fourth quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock worth $120,000 after buying an additional 7,509 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of CalciMedica in the third quarter worth about $67,000. Millennium Management LLC boosted its stake in CalciMedica by 30.5% during the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock valued at $255,000 after buying an additional 16,824 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in CalciMedica by 51.2% during the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after buying an additional 22,525 shares in the last quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.